↓ Skip to main content

The role of BRAF V600 mutation in melanoma

Overview of attention for article published in Journal of Translational Medicine, May 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#37 of 3,689)
  • High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

news
24 news outlets
blogs
2 blogs
twitter
3 tweeters
patent
4 patents
facebook
1 Facebook page
wikipedia
4 Wikipedia pages

Citations

dimensions_citation
430 Dimensions

Readers on

mendeley
869 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The role of BRAF V600 mutation in melanoma
Published in
Journal of Translational Medicine, May 2012
DOI 10.1186/1479-5876-10-85
Pubmed ID
Authors

Paolo A Ascierto, John M Kirkwood, Jean-Jacques Grob, Ester Simeone, Antonio M Grimaldi, Michele Maio, Giuseppe Palmieri, Alessandro Testori, Francesco M Marincola, Nicola Mozzillo

Abstract

BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 869 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 <1%
India 2 <1%
Germany 1 <1%
Brazil 1 <1%
Ecuador 1 <1%
Italy 1 <1%
Mexico 1 <1%
Canada 1 <1%
Denmark 1 <1%
Other 1 <1%
Unknown 856 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 191 22%
Student > Ph. D. Student 163 19%
Student > Master 142 16%
Researcher 79 9%
Other 40 5%
Other 101 12%
Unknown 153 18%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 249 29%
Medicine and Dentistry 157 18%
Agricultural and Biological Sciences 138 16%
Pharmacology, Toxicology and Pharmaceutical Science 35 4%
Chemistry 25 3%
Other 89 10%
Unknown 176 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 193. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 December 2021.
All research outputs
#148,481
of 21,364,317 outputs
Outputs from Journal of Translational Medicine
#37
of 3,689 outputs
Outputs of similar age
#580
of 143,176 outputs
Outputs of similar age from Journal of Translational Medicine
#1
of 1 outputs
Altmetric has tracked 21,364,317 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,689 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,176 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them